ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cyclosporine

Also written as “cyclosporine”, “Cyclosporine A” and “Ciclosporin”.

Its studies are mostly in Dry Eye Syndromes · Dermatitis, Atopic · Bronchiolitis Obliterans Syndrome · Conjunctivitis, Allergic · Bronchiolitis Obliterans, led by 26 companies.

Drug pageCyclosporine: every studyMany companies study it; this page follows only the 81 they lead. All 388 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 6, 200581 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only220 open or runningphase 4since Sep 6, 2005Sep 6, 2005none ahead
Pfizerits history only80 open or runningphase 4since Sep 13, 2005Jun 30, 2004none ahead
Hoffmann-La Rocheits history only70 open or runningphase 4since Jun 30, 2005Jun 30, 2005none ahead
Santen Pharmaceuticalits history only50 open or runningphase 3since May 19, 2006May 19, 2006none ahead
AbbVieits history only40 open or runningphase 4since Apr 22, 2014Apr 17, 2009none ahead
Zambon SpAits history only40 open or runningphase 3since Aug 30, 2018Aug 30, 2018none ahead
Sirion Therapeuticsits history only30 open or runningphase 3since Jul 13, 2007Jul 13, 2007none ahead
Amsterdam Molecular Therapeuticsits history only20 open or runningphase 3since Apr 30, 2009Apr 30, 2009none ahead
APT Pharmaceuticalsits history only20 open or runningphase 3since Sep 17, 2008Sep 17, 2008none ahead
Hanlim Pharm.its history only20 open or runningphase 3since Dec 10, 2012Dec 10, 2012none ahead
Sigmoid Pharma20 open or runningphase 2since Dec 15, 2009Dec 15, 2009none ahead

Also a collaborator on its studies: Parexel, Dr. Falk Pharma, Syreon and The Clinical Trial.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sigmoid Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2009First study: phase 2 study in Mild to Moderate Ulcerative ColitisFirst studyNCT01033305 · 118 enrolled · Ireland, United Kingdom
  2. Apr 22, 2014Phase 1 study in HealthyNCT02130414 · 48 enrolled

TargetBeta

PPIA →read by rule
“Cyclophilin A modulator”ChEMBL 37, by rule

Studies

All 2 Sigmoid Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02130414Healthy1CompletedJan 201548
NCT01033305Mild to Moderate Ulcerative Colitis · Ireland, United Kingdom2CompletedAug 2011118

How it is read

Names in the registry

  • “cyclosporine”, 12 entries
  • “Cyclosporine”, 10 entries
  • “Cyclosporine A”, 6 entries
  • “Ciclosporin”, 4 entries
  • “Liposomal Cyclosporine A”, 3 entries

Codes read as this program: NOVA22007.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.